About FDA

Materials from Webinar on Access to Investigational Drugs

Do you have questions about the use of investigational drugs for treatment purposes?

Expanded access, sometimes called "compassionate use," is the use of an investigational drug outside of a clinical trial to treat a patient with a serious or immediately life-threatening disease or condition who has no comparable or satisfactory alternative treatment options.

On Tuesday, February 23, at 3 p.m. ET, the FDA hosted a 30-minute webinar on Access to Investigational Drugs. The featured speakers, Theresa Toigo, Director, Office of Special Health Issues and Richard Klein, HIV/AIDS Program Director, Office of Special Health Issues, discussed factors to consider in deciding whether to seek access to an investigational drug and the ways to access investigational drugs.

Title: Access to Investigational Drugs
Duration: 00:34:07
Web address for viewing: https://webmeeting.nih.gov/p14874544/

Download presentation slides (PDF)

Page Last Updated: 08/11/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English